What is Calypso Biotech?
Calypso Biotech operates as a specialized immunotherapy enterprise, originating as a strategic spin-off from Merck Serono. The company is dedicated to the discovery and development of novel monoclonal antibodies designed to treat immune-mediated diseases characterized by significant unmet medical needs. Headquartered in Amsterdam, the Netherlands, with critical research operations in Geneva, Switzerland, the firm maintains a robust operational footprint. Furthermore, its status as a resident company at Johnson & Johnson Innovation JLABS in Beerse, Belgium, highlights its integration into a premier life science ecosystem, facilitating accelerated research and development cycles for its therapeutic pipeline.
How much funding has Calypso Biotech raised?
Calypso Biotech has raised a total of $16.1M across 1 funding round:
Series A
$16.1M
Series A (2019): $16.1M, investors not publicly disclosed
Key Investors in Calypso Biotech
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Calypso Biotech?
Following this major enterprise-level funding, Calypso Biotech is positioned to scale its clinical development programs and expand its research capabilities. The strategic allocation of this capital will likely focus on advancing lead candidates through preclinical and early-stage clinical trials, while simultaneously strengthening its intellectual property portfolio. By leveraging its presence within the JLABS incubator, the company is well-equipped to navigate the complexities of drug development, aiming to deliver transformative treatments for patients suffering from chronic immune pathologies. Future growth will likely center on strategic partnerships and the potential for further pipeline diversification as the firm matures into a clinical-stage powerhouse.
See full Calypso Biotech company page
